The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Notice for vutrisiran (Alnylam Australia Pty Ltd)
Active ingredients
vutrisiran
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Subcutaneous injection
Indication
Treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in patients with polyneuropathy
Therapeutic area
Inherited metabolic disorders